Rezdifra is a novel drug, but its specific information is not included in the current search results. According to the existing information, the search results mainly involve detailed information on drugs such as riptinib and remitinib, but do not mention the relevant indications or treatment areas of rosmertinib.

1. Relevant drug references

(1) Riptinib: Used for the treatment of ROS1 positive non-small cell lung cancer and NTRK positive solid tumors, approved in the United States in 2023 and entered Chinese medical insurance in 2024.

(2) Remdesidine: a melatonin receptor agonist, suitable for insomnia patients with difficulty falling asleep, was launched in the United States in 2005.

(3) Leporesin: an appetite suppressant used for the treatment of insomnia, approved by the FDA in 2019 and approved in China in 2025.

2 drug development directions

(1) Targeted therapy: Current drug development focuses on specific gene mutations or protein targets, such as EGFR, ROS1, etc.

(2) Precision medicine: The new generation of drugs emphasizes individualized treatment strategies based on molecular typing.

(3) Combination therapy: Drug development tends to explore combination therapy regimens, such as targeting the MEK signaling pathway with bimetinib.